Zhejiang Huayi Pharmaceutical Co., Ltd.
As of 20 November 2026, for the company name Zhejiang Huayi Pharmaceutical Co., Ltd. as recorded, 3 applications with this name as first applicant are listed as under review at China's CDE; the CDE acceptance records name it as first applicant on 15 records, across 7 drug names; the chemical-drug catalogue lists 6 active records with this name as holder; 19 active API registrations list this name as first registered company; 3 further acceptance records name it after the first applicant.
Check drug filings and source records for this company-name string.
Listed by the company name as recorded in the source, without merging affiliated entities.
Page reference
These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/20.
Drug filings
15 acceptance records as first applicant, grouped into 7 source drug names. Source data as of 2026/11/20.
Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.
Brexpiprazole Tablets 4 records · Latest accepted 2026/06/10
Generic · 4
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2601356 | Generic | 2026/06/10 | Zhejiang Huayi Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHS2601355 | Generic | 2026/06/10 | Zhejiang Huayi Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHS2500281 | Generic | 2025/01/14 | Zhejiang Huayi Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHS2500280 | Generic | 2025/01/14 | Zhejiang Huayi Pharmaceutical Co., Ltd. | CDE ↗ |
Empagliflozin Tablets 5 records · Latest accepted 2026/05/14
Supplement · 5
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2600949 | Supplement | 2026/05/14 | Zhejiang Huayi Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHB2600948 | Supplement | 2026/05/14 | Zhejiang Huayi Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHB2500306 | Supplement | 2025/02/18 | Zhejiang Huayi Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHB2500305 | Supplement | 2025/02/18 | Zhejiang Huayi Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHB2302139 | Supplement | 2023/09/21 | Zhejiang Huayi Pharmaceutical Co., Ltd. | CDE ↗ |
甲磺酸贝舒地尔片 · No verified English name 1 records · Latest accepted 2025/06/04
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2501976 | Generic | 2025/06/04 | Zhejiang Huayi Pharmaceutical Co., Ltd. | CDE ↗ |
Vonoprazan Fumarate Tablets 1 records · Latest accepted 2025/02/08
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2500639 | Generic | 2025/02/08 | Zhejiang Huayi Pharmaceutical Co., Ltd. | CDE ↗ |
Ibrutinib Capsules 1 records · Latest accepted 2024/08/23
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2402752 | Generic | 2024/08/23 | Zhejiang Huayi Pharmaceutical Co., Ltd. | CDE ↗ |
Dapagliflozin Tablets 2 records · Latest accepted 2023/07/21
Generic · 2
Canagliflozin Tablets 1 records · Latest accepted 2022/07/11
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2201048 | Generic | 2022/07/11 | Zhejiang Huayi Pharmaceutical Co., Ltd. | CDE ↗ |
Changes in the last 90 days
0 events from 2026/08/24 to 2026/11/21. CDE data as of 2026/11/20; NMPA data as of 2026/11/20.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.
- No matching records were found in the currently loaded source data; coverage dates are listed below.
Under review
3 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/20.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| Brexpiprazole Tablets | CYHS2601356 | Generic | 2026/06/10 | Zhejiang Huayi Pharmaceutical Co., Ltd. | CDE ↗ |
| Brexpiprazole Tablets | CYHS2601355 | Generic | 2026/06/10 | Zhejiang Huayi Pharmaceutical Co., Ltd. | CDE ↗ |
| 甲磺酸贝舒地尔片 · No verified English name | CYHS2501976 | Generic | 2025/06/04 | Zhejiang Huayi Pharmaceutical Co., Ltd. | CDE ↗ |
Catalogue holder records
6 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/20. Manufacturer-only records are excluded.
| Drug | Marketing authorization holder | Manufacturer | NMPA approval no. | Approved | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Vonoprazan Fumarate Tablets | Zhejiang Huayi Pharmaceutical Co., Ltd. | Zhejiang Huayi Pharmaceutical Co., Ltd. | 国药准字H20266228 | 2026/10/13 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Ibrutinib Capsules | Zhejiang Huayi Pharmaceutical Co., Ltd. | Zhejiang Huayi Pharmaceutical Co., Ltd. | 国药准字H20264337 | 2026/05/19 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Dapagliflozin Tablets | Zhejiang Huayi Pharmaceutical Co., Ltd. | Zhejiang Huayi Pharmaceutical Co., Ltd. | 国药准字H20249541 | 2024/12/01 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Dapagliflozin Tablets | Zhejiang Huayi Pharmaceutical Co., Ltd. | Zhejiang Huayi Pharmaceutical Co., Ltd. | 国药准字H20249540 | 2024/12/01 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Empagliflozin Tablets | Zhejiang Huayi Pharmaceutical Co., Ltd. | Zhejiang Huayi Pharmaceutical Co., Ltd. | 国药准字H20247122 | 2024/06/07 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Canagliflozin Tablets | Zhejiang Huayi Pharmaceutical Co., Ltd. | Zhejiang Huayi Pharmaceutical Co., Ltd. | 国药准字H20243612 | 2024/04/24 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.
API registrations
19 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/20.
| Name | Company / applicant | Registration number | Status | Source update date | View source |
|---|---|---|---|---|---|
| 甲磺酸贝舒地尔 · No verified English name | Zhejiang Huayi Pharmaceutical Co., Ltd. | Y20250000081 | A | 2026/09/07 | CDE ↗ |
| 伊布替尼 · No verified English name | Zhejiang Huayi Pharmaceutical Co., Ltd. | Y20240000629 | A | 2026/09/21 | CDE ↗ |
| 马来酸美凡厄替尼 · No verified English name | Zhejiang Huayi Pharmaceutical Co., Ltd. | Y20240000399 | A | 2025/10/30 | CDE ↗ |
| 吗啉硝唑 · No verified English name | Zhejiang Huayi Pharmaceutical Co., Ltd. | Y20230001123 | A | 2026/07/09 | CDE ↗ |
| 司来帕格 · No verified English name | Zhejiang Huayi Pharmaceutical Co., Ltd. | Y20220001259 | A | 2024/12/11 | CDE ↗ |
| 奥泽沙星 · No verified English name | Zhejiang Huayi Pharmaceutical Co., Ltd. | Y20220000207 | I | 2022/03/24 | CDE ↗ |
| 瑞戈非尼 · No verified English name | Zhejiang Huayi Pharmaceutical Co., Ltd. | Y20220000148 | A | 2024/04/26 | CDE ↗ |
| 阿普米司特 · No verified English name | Zhejiang Huayi Pharmaceutical Co., Ltd. | Y20210000113 | A | 2025/12/09 | CDE ↗ |
| 马昔腾坦 · No verified English name | Zhejiang Huayi Pharmaceutical Co., Ltd. | Y20200001281 | A | 2025/09/06 | CDE ↗ |
| 枸橼酸托法替布 · No verified English name | Zhejiang Huayi Pharmaceutical Co., Ltd. | Y20200001214 | A | 2024/01/17 | CDE ↗ |
| 卡格列净 · No verified English name | Zhejiang Huayi Pharmaceutical Co., Ltd. | Y20200001023 | A | 2026/03/06 | CDE ↗ |
| 恩格列净 · No verified English name | Zhejiang Huayi Pharmaceutical Co., Ltd. | Y20190021274 | A | 2026/06/02 | CDE ↗ |
| 奥美拉唑 · No verified English name | Zhejiang Huayi Pharmaceutical Co., Ltd. | Y20190008313 | A | 2023/12/02 | CDE ↗ |
| 奥美拉唑钠 · No verified English name | Zhejiang Huayi Pharmaceutical Co., Ltd. | Y20190007218 | A | 2024/01/17 | CDE ↗ |
| 盐酸环丙沙星 · No verified English name | Zhejiang Huayi Pharmaceutical Co., Ltd. | Y20190002570 | A | — | CDE ↗ |
| 辛伐他汀 · No verified English name | Zhejiang Huayi Pharmaceutical Co., Ltd. | Y20190002257 | A | — | CDE ↗ |
| 米拉贝隆 · No verified English name | Zhejiang Huayi Pharmaceutical Co., Ltd. | Y20190000765 | A | 2026/05/20 | CDE ↗ |
| 琥珀酸索利那新 · No verified English name | Zhejiang Huayi Pharmaceutical Co., Ltd. | Y20180000737 | A | 2025/04/29 | CDE ↗ |
| 非布司他 · No verified English name | Zhejiang Huayi Pharmaceutical Co., Ltd. | Y20170001633 | A | 2026/02/10 | CDE ↗ |
Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.
Co-applicant records
3 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/20.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| Regorafenib Tablets | CYHB2400768 | Supplement | 2024/06/06 | Hunan Ming Rui Pharmaceutical Co., Ltd. romanized; Zhejiang Huayi Pharmaceutical Co., Ltd. | CDE ↗ |
| Everolimus Tablets | CYHS2301019 | Generic | 2023/04/10 | Zhejiang Kangrun Pharmaceutical Co., Ltd; Zhejiang Huayi Pharmaceutical Co., Ltd. | CDE ↗ |
| Everolimus Tablets | CYHS2301018 | Generic | 2023/04/10 | Zhejiang Kangrun Pharmaceutical Co., Ltd; Zhejiang Huayi Pharmaceutical Co., Ltd. | CDE ↗ |
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/20
- Chemical-drug catalogue
- Last successful update: 2026/11/20
- API registrations
- Last successful update: 2026/11/20
- NMPA drug delivery notices
- Last successful update: 2026/11/20
Loaded notices dated 2026-11-06 to 2026-11-20; 0 notices not yet loaded. Covers loaded notices only, not a complete historical approval database.
Listed by the company name as recorded in the source, without merging affiliated entities.
This page summarizes loaded records only. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.
Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.
Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.